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Abstract: BACKGROUND Randomized controlled trials (RCTs) data demonstrate that sevoflurane
postconditioning improves clinical outcomes of liver resection with inflow occlusion, presumably due to
hepatocyte protection from ischemic injury. However, mechanisms remain unclear. This study exam-
ines liver biopsy samples obtained in an RCT of sevoflurane postconditioning to test the hypothesis that
sevoflurane attenuates hepatocyte apoptosis. METHODS Messenger ribonucleic acid (mRNA) of pro- and
antiapoptotic regulators Bax and B-cell lymphoma 2 (Bcl2) was examined in hepatic biopsies obtained
during the RCT. Hepatic stellate cells (HSCs) and hepatocytes were exposed to hypoxia/reoxygenation
(H/R) in vitro to evaluate the effect of sevoflurane postconditioning on apoptosis. The role of HSC as a
potential apoptosis trigger in hepatocytes through the production of reactive oxygen species induced by
H/R was explored by transferring supernatants from H/R-exposed HSC to hepatocytes as target cells.
RESULTS In patients of the RCT, the Bax/Bcl2 mRNA ratio in liver tissue was markedly decreased in
the sevoflurane arm (25% ± 21% reduction; P = .001). In vitro, H/R increased reactive oxygen species
production in HSC by 33% ± 16% (P = .025), while it was abolished in the presence of sevoflurane (P <
.001). In hepatocytes, caspase was minimally activated by H/R. However, incubation of hepatocytes with
supernatants of HSC, previously exposed to H/R, increased caspase activity by 28% ± 13% (P < .001).
When exposed to supernatants from HSC undergoing sevoflurane postconditioning, caspase activation in
hepatocytes was reduced by 20% ± 9% (P < .001), similarly to the sevoflurane effect on the BAX/Bcl2
mRNA ratio in the liver samples. CONCLUSIONS The study shows that sevoflurane postconditioning
affects apoptosis of hepatocytes after ischemia-reperfusion injury in patients. It also demonstrates that
HSC may be the effector cells of sevoflurane protection.
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In liver surgery, inflow occlusion (Pringle maneuver) may, at times, be unavoidable to decrease extensive bleeding during resection.1 Blood loss requiring transfu-
sion is well known to correlate with poor outcomes,2 includ-
ing a decrease of cancer-free survival.3 However, the Pringle 
maneuver with interruption of oxygen (O2) and nutritional 
supply induces hepatocyte ischemia-reperfusion (I/R) 
injury, which is surprisingly well tolerated by the liver but 
has been shown to cause poor outcomes when used over 
longer periods of time.4,5
Inflow ischemia followed by reperfusion with portal 
and arterial blood leads to increased levels of aspartate 
KEY POINTS
• Question: What is the protective mechanism of sevoflurane postconditioning in ischema-
reperfusion injury in the liver? What findings will be expected in vivo analyzed in liver biopsies, 
based on a randomized control trial, or in vitro in hepatocytes and hepatic stellate cells?
• Finding: Pharmacological postconditioning with the volatile anesthetic sevoflurane attenuates 
ischemic injury-induced apoptosis in hepatocytes through interaction with hepatic stellate 
cells, which are the injury sensing and transmitting cells through production of reactive oxygen 
species.
• Meaning: An important mechanism of sevoflurane protection in ischemic injury in hepatocytes 
is an indirect effect of sevoflurane on hepatic stellate cells.
BACKGROUND: Randomized controlled trials (RCTs) data demonstrate that sevoflurane post-
conditioning improves clinical outcomes of liver resection with inflow occlusion, presumably due 
to hepatocyte protection from ischemic injury. However, mechanisms remain unclear. This study 
examines liver biopsy samples obtained in an RCT of sevoflurane postconditioning to test the 
hypothesis that sevoflurane attenuates hepatocyte apoptosis.
METHODS: Messenger ribonucleic acid (mRNA) of pro- and antiapoptotic regulators Bax and B-cell 
lymphoma 2 (Bcl2) was examined in hepatic biopsies obtained during the RCT. Hepatic stellate 
cells (HSCs) and hepatocytes were exposed to hypoxia/reoxygenation (H/R) in vitro to evaluate 
the effect of sevoflurane postconditioning on apoptosis. The role of HSC as a potential apoptosis 
trigger in hepatocytes through the production of reactive oxygen species induced by H/R was 
explored by transferring supernatants from H/R-exposed HSC to hepatocytes as target cells.
RESULTS: In patients of the RCT, the Bax/Bcl2 mRNA ratio in liver tissue was markedly decreased 
in the sevoflurane arm (25% ± 21% reduction; P = .001). In vitro, H/R increased reactive oxygen 
species production in HSC by 33% ± 16% (P = .025), while it was abolished in the presence 
of sevoflurane (P < .001). In hepatocytes, caspase was minimally activated by H/R. However, 
incubation of hepatocytes with supernatants of HSC, previously exposed to H/R, increased 
caspase activity by 28% ± 13% (P < .001). When exposed to supernatants from HSC undergo-
ing sevoflurane postconditioning, caspase activation in hepatocytes was reduced by 20% ± 9% 
(P < .001), similarly to the sevoflurane effect on the BAX/Bcl2 mRNA ratio in the liver samples.
CONCLUSIONS: The study shows that sevoflurane postconditioning affects apoptosis of hepa-
tocytes after ischemia-reperfusion injury in patients. It also demonstrates that HSC may be the 
effector cells of sevoflurane protection.  (Anesth Analg 2018;127:1058–65)
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aminotransferase and alanine aminotransferase, which are 
markers of hepatocyte injury. During inflow ischemia, ade-
nosine triphosphate production decreases with the ultimate 
consequence of loss of function of the cellular membrane 
ion pump, swelling of the cell, and, finally, disruption of the 
cellular membrane structure, a process known as “necro-
sis.” At the same time, reactive oxygen species (ROS) is 
produced, which further supports necrosis but also triggers 
apoptosis, which is a hallmark of I/R injury in hepatocytes.6 
Under normal conditions, proapoptotic Bax and antiapop-
totic B-cell lymphoma 2 (Bcl2) proteins in hepatocytes keep 
an elaborate balance.7 An increase of the expression of Bax 
and/or a decrease of Bcl2 enhances downstream activity 
of caspase-3, which propagates apoptotic cell death. As 
recently shown, hepatic stellate cells (HSCs) play a crucial 
role in inflammatory signaling to hepatocytes.8
Many studies have been performed to identify protective 
clinical maneuvers for hepatocytes undergoing I/R injury 
in the perioperative phase. One approach intervenes dur-
ing the time period after the injury has just occurred and is 
called “postconditioning.” Postconditioning was found to 
be effective to attenuate I/R injury after an ischemic event 
to myocardium in randomized clinical studies.9 A similar 
approach is used in I/R injury to the liver induced by inflow 
occlusion, applying ischemic or pharmacological postcondi-
tioning.10,11 A randomized controlled trial (RCT) showed the 
benefit of briefly applying the volatile anesthetic sevoflurane 
at the beginning of the reperfusion phase.12 Besides the fact 
that aspartate aminotransferase and alanine aminotransferase 
peak values were diminished in the postconditioning group, 
patients of this arm also experienced fewer complications.12 
While these data suggest a beneficial effect of pharmacological 
postconditioning, the mechanism of protection is not known.
This study focuses on apoptosis as 1 possible effector 
pathway of sevoflurane postconditioning in I/R injury, 
where the process of apoptosis plays a crucial role.6 Biopsies 
from an RCT12 were analyzed. Data were supplemented by 
experiments using an I/R injury model in hepatocytes in 
cell culture. It was hypothesized that sevoflurane has an 
impact on rates of hepatocyte apoptosis. Second, it was pos-
tulated that HSCs, but not hepatocytes, mediate the protec-
tive effect of sevoflurane.
METHODS
Ethics
The study was approved by the institutional review board 
of the “Kantonale Ethikkommission,” Zurich, Switzerland 
(Ethical Committee N° StV 34–2007, Chairperson Professor 
Robert Maurer), on January 14, 2008. Written informed con-
sent was obtained from all subjects.
Biopsies From Randomized Controlled Study
From January 2008 to September 2010, patients were enrolled 
in an RCT at the University Hospital Zurich, Switzerland 
(NCT00518908).12 The trial was conducted to assess whether 
pharmacological postconditioning provides hepatocyte pro-
tection after inflow occlusion (Pringle maneuver) during 
liver resection. Patients were randomized into 1 of 3 groups: 
(1) postconditioning group: propofol anesthesia with inflow 
occlusion of ≥30 minutes; on reperfusion, propofol infusion 
was stopped, and sevoflurane was flushed in for 5 minutes, 
followed by exposure to sevoflurane with an end-tidal con-
centration of 3.2 Vol% for 10 minutes, and then a washout 
phase of sevoflurane and reinitiating propofol infusion. (2) 
Intermittent inflow occlusion control arm: propofol anes-
thesia with inflow occlusion for 15 minutes, followed by a 
reperfusion time of 5 minutes, which was repeated ≥1 time to 
reach a total occlusion time of a minimum of 30 minutes. (3) 
Continuous inflow occlusion control arm: propofol anesthesia 
for the entire procedure with a Pringle time of ≥30 minutes.
In the trial, patient allocation ratio was 3:3:1 based on 
the sample size calculation. Before inflow occlusion and 
45 minutes after reperfusion, a biopsy of liver tissue was 
obtained, a procedure that had been approved by the 
Ethic Committee in the protocol of the RCT NCT00518908. 
Biopsies were immediately snap frozen in liquid nitrogen. 
In this study, we only evaluated biopsies from patients in 
the postconditioning and control arms.
RNA Extraction and Real-Time Polymerase Chain 
Reaction of Liver Biopsies
Total ribonucleic acid (RNA) from liver biopsies was iso-
lated by homogenization using 1.4-mm ceramic beads 
(MagNA Lyser Green Beads; Roche Diagnostics Switzerland, 
Rotkreuz, Switzerland) and a Precellys homogenizer (Bertin 
Corp, Rockville, MD) for 2 × 30 seconds at 6800 rpm, fol-
lowed by a purification step with the RNeasy Minikit 
(Qiagen, Basel, Switzerland). The total amount of RNA was 
determined at absorbance of 260 nm, purity based on the 
r260/280 nm ratio using NanoDrop ND 1000 (NanoDrop 
Technologies, Wilmington, DE). Complementary deoxyri-
bonucleic acid (cDNA) was produced using 0.2-µg RNA for 
the reaction in the cDNA reverse transcription kit (Qiagen, 
Basel, Switzerland). Quantitative polymerase chain reac-
tion was performed with the help of the FastStart Universal 
Probe Master Polymerase Chain Reaction Mix (Roche, 
Basel, Switzerland) with labeled probes (Roche Probe 
Library, Basel, Switzerland) and respective primers for Bax 
and Bcl2 (Microsynth, Balgach, Switzerland) (Table). The 
comparative cycle threshold method was used for quanti-
fication of the gene expression. The crossing point values 
(Secondary Derivative Method; Roche, Basel, Switzerland) 
of the samples were normalized to the housekeeping gene 
(18S). Relative messenger ribonucleic acid (mRNA) changes 
Table. Primer and Probe Sequences Used for Real-
Time PCR
Gene Primer Sequence
Length of  
Amplicon
Bax  104 nT
 Forward 5′ ATG TTT TCT GAC GGC AAC TTC 3′  
 Reverse 5′ ATC AGT TCC GGC ACC TTG 3′  
 Probe #57 5′ GGC CCC AG 3′  
Bcl2  96 nT
 Forward 5′ GCA CCT GCA CAC CTG GAT 3′  
 Reverse 5′ AGC CAG GAG AAA TCA AAC AGA G 3′  
 Probe #57 5′ ACC TGC TG 3′  
18S  96 nT
 Forward 5′ GGA GAG GGA GCC TGA GAA AC 3′  
 Reverse 5′ TGC GGA GTG GGT AAT TTG C 3′  
 Probe #74 5′ GGC AGC AG 3′  
Abbreviations: Bcl2, B-cell lymphoma 2; PCR, polymerase chain reaction.
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of the biopsies after reperfusion compared to the value 
before reperfusion were calculated for each patient.
Cell Lines
HSCs (LX-2) were generated by spontaneous immortaliza-
tion in low-serum conditions.13 This cell line, a generous 
gift from Professor Dr Scott Friedman, Mount Sinai School 
of Medicine, New York, NY, was cultured in Dulbecco’s 
Modified Eagle’s Medium high glucose (Gibco, Life 
Technologies, Zug, Switzerland), 10% fetal bovine serum 
(Gibco, Life Technologies, Zug, Switzerland), and 1% peni-
cillin/streptomycin (final concentration: 100 U/mL penicil-
lin, 100 μg/mL streptomycin; Gibco, Life Technologies, Zug, 
Switzerland). When confluence was reached, experiments 
with HSCs were started.
Hepatocytes (Hep3B), a human hepatoma cell line,14 
were a kind gift of Dr Bruno Stieger, Division of Clinical 
Pharmacology and Toxicology, University Hospital Zurich, 
Zurich, Switzerland. Their culture medium consists of 
Dulbecco’s Modified Eagle’s Medium with high glucose, 
110 mg/L sodium pyruvate, 10% fetal bovine serum, and 
1% penicillin/streptomycin. Hepatocytes were seeded at 
25,000/mL growth for 2 days until 90% confluence.
Exposure to Hypoxia/Reoxygenation
In a first approach, confluent hepatocytes were exposed to 
0.2% O2 for 6 hours and reoxygenated in air (21% O2) for 
24 hours (hypoxia/reoxygenation [H/R]), with or without 
the presence of 2.2 Vol% sevoflurane in the reoxygenation 
phase. The lowest O2 concentration that can be reached in 
the hypoxic chamber is 0.2%. The constellation of 6-hour 
hypoxia/24-hour reoxygenation was chosen even not directly 
comparable to the in vivo scenario because lower exposure 
times do not induce apoptosis according to preliminary find-
ing of our group. In a similar approach, HSCs were exposed to 
hypoxia for 6 hours and reoxygenated in air (21% O2) for a 2- 
or 24-hour reoxygenation phase with or without the presence 
of 2.2 Vol% sevoflurane. DNA content and caspase activity 
were determined in both cell types. Sevoflurane was present 
during the entire reoxygenation phase (2 or 24 hours).
DNA Quantitation
The fluorescent dye, bisbenzimide H 33258 (Hoechst 33258), 
is specific for DNA quantitation (range, 10 ng/mL to 
10 μg/mL). A DNA quantitation assay with fluorescence 
measurement was performed using a Tecan reader (excitation 
of 360 nm, emission at 460 nm) (Sigma, Buchs, Switzerland).15
Caspase Assay
Caspases are aspartate-directed cysteine proteases, which 
cleave a group of intracellular substrates and thereby con-
tribute to apoptosis. Various physiological and pathologi-
cal stimuli can activate the inactive precursor proteases. To 
identify and quantify caspase-3/7/8 activity in apoptotic 
cells, the fluorogenic tetrapeptide substrate N-Acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
is a useful tool. The fluorogenic 7-amino-4-methylcoumarin 
(AMC) residue is released by caspase activity, and quanti-
fication is performed with the help of a spectrofluorometer 
(3607465 nm/Tecan infinite M200Pro; Tecan Group Ltd, 
Maennedorf, Switzerland). This experimental approach was 
performed using a commercially available kit (Ac-DEVD-
AMC; PeptaNova, Sandhausen, Germany) following the 
provider’s protocol.
Determination of Intracellular ROS
2′,7′-Dichlorodihydrofluorescein diacetate (H2DCF-DA) 
(Sigma-Aldrich, Buchs, Switzerland) was used to assess the 
intracellular levels of ROS. After penetration into the cells, 
H2DCF-DA is hydrolyzed to 2′,7′-dichlorodihydrofluores-
cein by the cellular esterases. In a following step, 2′,7′-dichlo-
rodihydrofluorescein is oxidized by intracellular ROS to the 
highly fluorescent compound 2′,7′-dichlorofluorescein.
After a treatment of 6 hours of hypoxia and a short reox-
ygenation of 2 hours to guarantee detection of ROS, cells 
were washed and further incubated in a medium containing 
50 μM H2DCF-DA for 10 minutes. Fluorescence was mea-
sured with a microplate spectrofluorometer (Tecan infinite 
M200Pro), where excitation and emission wavelengths were 
set to 485 and 528 nm, respectively. As a positive control, 
Sin-1 was used in a final concentration of 200 μM (Molecular 
Probes; Thermo Fisher Scientific, Reinach, Switzerland).
Determination of Hydrogen Peroxide in the 
Supernatant
Reduction of O2 produces superoxide, an important compo-
nent of the group of ROS, which through dismutation forms 
hydrogen peroxide (H2O2). H2O2 content in supernatants 
of HSCs was determined using the Amplex (N-acetyl-3,7-
dihydroxyphenoxazine) Red Hydrogen Peroxide/Peroxidase 
Assay Kit (Invitrogen by Thermo Fisher/Life Technologies, 
Zug, Switzerland). Cells were exposed to hypoxia 0.2% for 6 
hours, followed by a 2-hour reoxygenation phase with air, 2.2 
Vol% sevoflurane or air/N-acetyl-cysteine (NAC; ROS inhib-
itor, 10 mM). Eight hours of normoxia was used as the control 
condition. The Amplex Red Hydrogen Peroxide/Peroxidase 
technique is widely used to detect extracellular H2O2. It has 
high sensitivity and specificity.
H2O2 is of particular interest compared to ROS elements 
because the former is rather stable. It diffuses actively 
and freely through the cell membranes, and it can gener-
ate locally the hydroxyl radicals by iron-mediated Fenton 
reaction. The Amplex Red reagent reacts with H2O2 in a 
1:1 stoichiometry to produce the red-fluorescent oxidation 
product, resorufin, measured at 540/590 nm.
The supernatants of the cells in different conditions were 
used (50-µL aliquots were taken from each well of a 96-stripe 
well plate), and the concentration of H2O2 was measured 
according to the protocol provided by the manufacturer.
Use of NAC as Antioxidant (Positive Control for 
Blocking Step)
HSCs were incubated for 6 hours in hypoxia, followed by 
a 2-hour reoxygenation with normal air in the presence or 
absence of the antioxidant NAC (10 mM) (Sigma, Buchs, 
Switzerland).16
Supernatant Transfer Model
Supernatants from HSCs (H/R 6 hours/2 hours) were 
removed, centrifuged, and carefully added to a monolayer 
Copyright © 2018 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
       
October 2018 • Volume 127 • Number 4 www.anesthesia-analgesia.org 1061
of hepatocytes for 24 hours. Due to the fast activation of 
ROS, the 2-hour reoxygenation time point was chosen. 
DNA and caspase activity were determined in hepatocytes.
Statistical Analysis
Data are presented as mean ± standard deviation. Statistical 
analyses were performed in GraphPad Prism 6.0 for Mac 
(GraphPad Inc, La Jolla, CA). Data were tested for normal-
ity by Shapiro-Wilks normality test. For the comparison of 2 
groups, an unpaired 2-tailed Student t test of normally dis-
tributed data was performed (Figure 1A–C).
For the comparison of ≥3 groups, a 1-way analysis of 
variance was performed for normally distributed data. 
The mean of each group was compared to the mean of 
the reference group (H/R). A Holm-Sidak post hoc test 
was performed to correct for multiple comparisons 
(Figures 2B and 5A).
For comparison of ≥3 groups of not normally distributed 
data, a Kruskal-Wallis test was performed. The mean rank 
of each group was compared to the mean rank of the refer-
ence group (H/R). A Dunn post hoc test was performed to 
correct for multiple comparisons (Figures 2A, 3A, 3B, 4A, 
4B, and 5B). A flow chart indicates the path of the statistical 
analyses (Supplemental Digital Content, Figure 1, http://
links.lww.com/AA/C530). Multiplicity-adjusted P values 
are reported and considered significant if <.05.
At least 3 independent cell experiments were performed 
with ≥3 data points per experimental group. The exact num-
ber of independent experiments (n), the type of statistical 
tests performed, and adjusted P values can be found in the 
figure legend of all of the figures (Figures 1–5).
RESULTS
Liver Tissue
I/R is associated with an increased expression of the pro-
apoptotic regulator Bax, which is attenuated in the presence 
of sevoflurane postconditioning.
Bax and Bcl2 mRNA were measured in liver biopsies of 
study patients before and 45 minutes after inflow occlusion 
and compared with the sevoflurane group with postcondi-
tioning. At this early time point of reperfusion, determina-
tion of these markers seems to be reliable while caspase may 
not yet be activated.
In the presence of sevoflurane, Bax mRNA was reduced 
by 33% ± 38% (P = .02) (Figure  1A), while Bcl2 mRNA 
remained unchanged (Figure  1B). As a result, the Bax/
Bcl2 mRNA ratio decreased by 25% ± 21% in liver tissue 
exposed to sevoflurane compared to the control group 
(P = .02) (Figure 1C). This finding suggests less hepatocyte 
apoptosis in the sevoflurane-treated group, which may 
explain reduced “transaminitis” in the sevoflurane-treated 
Figure 1. mRNA expression of Bax and Bcl2 in liver biopsies before and after inflow occlusion. Bax (A) and Bcl2 (B) were determined in liver biop-
sies from the randomized controlled trial with sevoflurane postconditioning,12 and their Bax/Bcl2 ratio was calculated (C). Liver tissue, which was 
collected before the Pringle maneuver, served as baseline (T1). The second biopsy was taken 45 min after initiation of reperfusion (T2). The mRNA 
changes T2/T1 were calculated and are displayed as fold changes of the control group. Control refers to the arm with patients anesthetized through-
out the entire surgery with propofol. In the sevoflurane arm, propofol infusion was stopped at the end of ischemia and replaced by sevoflurane for 
10 min (3.2 Vol%). n = 17 in the control group, n = 48 in the sevoflurane group. #P = .02 for Bax and Bax/Bcl2. Groups have been compared by 
an unpaired 2-tailed Student t test. All data are presented as mean ± SD. Bcl2 indicates B-cell lymphoma 2; mRNA, messenger ribonucleic acid.
Figure 2. Exposure of HEPs to H/R: necrosis and apoptosis. HEPs 
were grown to confluence and exposed to 6 h of hypoxia (0.2% oxy-
gen) followed by 24 h of reoxygenation in air, with or without the 
presence of 2.2 Vol% sevoflurane. DNA quantitation was performed 
(A, n = 3, Kruskal-Wallis), and caspase activity was determined 
(B, n = 4, ANOVA). Data are presented as mean ± SD. All val-
ues are displayed as proportion of the control mean. *P < .001, #P < .001. ANOVA indicates analysis of variance; HEP, hepatocyte; 
H/R, hypoxia/reoxygenation; SD, standard deviation.
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group in the randomized study, leading to decreased peak 
levels of postoperative transaminases in the blood.12
Hypoxia-Reoxygenation Does Not Directly 
Trigger Apoptosis of Hepatocytes In Vitro
DNA quantification showed no evidence of hepatocyte cell 
death after 6 hours of hypoxia and 24 hours of reoxygen-
ation in vitro (Figure 2A), while the apoptosis rate increased 
by 5% ± 5% (P < .001). This increase was fully abrogated in 
the presence of sevoflurane (P < .001) (Figure 2B).
Hepatic Stellate Cells
Hypoxia-Reoxygenation Does Not Trigger Apoptosis in 
These Cells but Induces ROS Production, While Sevoflurane 
Decreases It. HSCs are the second most common liver 
cell type, and they were exposed to H/R injury in vitro. 
DNA decreased from 100% ± 5% to 94% ± 4% (P = .003), 
and sevoflurane postconditioning had no effect on DNA 
quantification (94% ± 5%) (Figure  3A). Caspase activity 
was not increased after reoxygenation (113% ± 23%; 
P = .07) but was reduced after reoxygenation with 
sevoflurane compared to reoxygenation with air (95% ± 
18%; P = .02) (Figure 3B).
In the next step, production of ROS and H2O2 by HSCs 
was explored following the hypothesis that ROS and H2O2 
may play a role in the orchestration of the H/R-induced 
inflammatory response by mediating injury. Six hours of 
hypoxia and 2 hours of reoxygenation were chosen because 
of the fast ROS and H2O2 responses on injury. Production 
of ROS in HSCs increased by 33% ± 16% after H/R injury 
(P = .025) but decreased to baseline after additional postcon-
ditioning with sevoflurane (P < .001) (Figure 4A). Production 
of H2O2 in HSCs increased by 16% on H/R injury (P = .015). 
This result was attenuated with sevoflurane postcondition-
ing (P < .001) (Figure 4B). NAC is a strong antioxidant and 
was used as a positive control. It completely blunted ROS 
and H2O2 production (both P < .001), while toxicity was 
excluded.
Transfer of HSC Supernatant to Hepatocytes: 
Supernatant Induces Hepatocyte 
Apoptosis, Which Is Blunted by Sevoflurane 
Postconditioning of HSCs
To explore a potentially indirect effect of H/R injury to hepa-
tocytes via HSCs, supernatant of HSCs with H/R injury was 
then transferred to Hep3B cells and incubated for 24 hours. 
Hepatocyte cell number did not change (Figure  5A), but 
caspase activity in hepatocytes exposed to HSC supernatant 
after H/R increased by 28% ± 13% (P < .001) (Figure 5B). 
Caspase activity in hepatocytes was attenuated by 20% ± 
9% when the supernatant was obtained from HSCs post-
conditioned with sevoflurane (P < .001). This decrease is 
comparable to the sevoflurane-induced attenuation of 25% 
of apoptosis markers in liver tissue biopsies (Figure  1C). 
Decreased caspase activity in hepatocytes was also demon-
strated after a 24-hour incubation with the supernatant of 
HSCs previously treated with NAC (P < .001) (Figure 5B).
DISCUSSION
This study combines translational findings from an RCT 
with an in vitro approach to explore why sevoflurane post-
conditioning protects from hepatocyte apoptosis after I/R 
injury to the liver. The in vitro model H/R injury in immor-
talized liver cell lines suggests that HSCs may transfer 
injury to hepatocytes by producing ROS, which is known 
to cause apoptosis of hepatocytes. In vitro, sevoflurane has 
no direct protective effect on hepatocytes but may have an 
indirect impact mediated by HSCs. This study presents the 
first in vitro data about HSCs as effectors of the liver-protec-
tive effect of sevoflurane.
Figure 3. Exposure of HSCs to H/R: necrosis and apoptosis. HSCs 
were grown to confluence and exposed to 6 h of hypoxia (0.2% oxy-
gen) followed by 24 h of reoxygenation in air (H/R), with or without 
the presence of 2.2 Vol% sevoflurane. DNA quantitation was per-
formed (A, n = 3, Kruskal-Wallis), and caspase activity was deter-
mined (B, n = 3, Kruskal-Wallis). Data are presented as mean ± 
SD. All values are displayed as proportion of the control mean. *P = .003, #P = .02. H/R indicates hypoxia/reoxygenation; HSC, 
hepatic stellate cell; SD, standard deviation.
Figure 4. Exposure of HSCs to H/R: production of ROS. HSCs were 
grown to confluence and exposed to 6 h of hypoxia (0.2% oxygen) 
followed by 2 h of reoxygenation in air (H/R), with or without the 
presence of 2.2 Vol% sevoflurane or NAC as antioxidant (10 μM). 
ROS (A, n = 3, Kruskal-Wallis) in HSC and H2O2 in supernatants of 
HSC (B, n = 5, Kruskal-Wallis) were determined. Data are presented 
as mean ± SD. All values are displayed as proportion of the control 
mean. *P = .025, #P < .001, $P < .001, +P = .015, çP < .001, 
£P < .001. H/R indicates hypoxia/reoxygenation; HSC, hepatic stel-
late cell; H2O2, hydrogen peroxide; NAC, N-acetyl-cysteine; ROS, reac-
tive oxygen species; SD, standard deviation.
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Pre- or postconditioning with volatile anesthetics is an 
effective protective strategy to decrease I/R injury to the liver. 
So far, its efficiency was tested in several models of hepatic 
I/R in humans12,17 as well as in vivo,18,19 showing decreased 
apoptosis and necrosis rate of hepatocytes. One possible 
mechanism involved in protection comprises involvement of 
hepatic energy metabolism.20 It has been demonstrated in rats 
that adenosine triphosphate content in the liver significantly 
decreases in the postischemic phase, which then may be par-
tially restored in the presence of sevoflurane.20 Another pos-
tulated pathway implies the production of nitric oxide, which 
is higher in the presence of sevoflurane in a model of rat liver 
transplantation.21 Schmidt et al22 showed that isoflurane pre-
conditioning in I/R injury in rats increases the expression of 
heme oxygenase-1 and emphasized its potential role in the 
protection provided by volatile anesthetics. These findings 
were further supported when a heme oxygenase-1 inducer was 
used instead of isoflurane.23 The idea that anesthetics modu-
late the ROS pathway in I/R injury is not new.24 However, it is 
generally believed that Kupffer cells and recruited neutrophils 
are the main source for ROS.25 In our study, we examined in 
vitro if HSCs may also be involved in an intercellular cross-talk 
involving ROS production to induce apoptosis in hepatocytes. 
While H/R does not induce hepatocytes apoptosis in our cell 
culture models, it triggers ROS production in HSCs, which in 
turn causes apoptosis of hepatocytes.
Hepatic I/R injury is a complex orchestration of intercel-
lular and intracellular pathways.26 The role of Kupffer cells for 
initiation of I/R injury has been better investigated.27–29 HSCs, 
however, are more common cell types in the liver and are 
constitutively present at the time of injury. Recent literature 
supports the claims for an important role of HSCs in inflam-
matory processes.8 Also, HSC depletion in mice demonstrated 
an attenuated I/R injury with less production of tumor necro-
sis factor-α and (C-X-C motif) ligand 1 as well as decreased 
infiltration with neutrophils, suggesting that HSCs are not 
an innocent bystander in inflammatory injury to the liver.8 
Similarly, in a model of pharmacological deactivation of HSCs 
through an endocannabinoid receptor type 2 agonist in I/R 
injury in mice, an attenuation of CD4+ T cell infiltration and 
reduced sinusoidal perfusion failure were observed.30 Given 
the complex functionality of HSCs, these findings are not sur-
prising.31 HSCs are well known as central regulators of the 
sinusoidal milieu, which requires fast adaptation to injury.31
There are several limitations to our study. First, superna-
tant transfer experiments do not allow direct contact of dif-
ferent cell types. However, it is an elegant method to obtain 
information about cell interaction without the complexi-
ties derived from direct cell–cell contact. The experimental 
approach is well established, and single-cell type-based 
assessment of intracellular signaling cascades is possible.32,33 
A second limitation emerges from the limitation of in vitro 
experiments using established cell lines. While Hep3B cells 
have hepatoma cell character, LX-2 cells are spontaneously 
immortalized cells. Apoptosis and ROS production may be 
altered by virtue of cell line-induced artefacts. A third limita-
tion is that this study does not present in vivo data on the 
effect size of HSCs in the I/R model. After all, stellate cells 
have a small cell body with long neuron-like extensions 
and make up only between 5% and 10% of the hepatic cell 
mass. The findings reported here need to be validated in an 
in vivo model of liver I/R injury and hepatocytes apoptosis 
after HSC depletion. But they may lay the ground for further 
testing of hypotheses regarding mechanisms of sevoflurane-
induced protection in hepatic I/R injury and possible also 
in other inflammatory models. Also, it should be pointed 
out that even though there is a strong correlation between 
sevoflurane conditioning and reduced apoptosis, the causal 
mechanism is not revealed in our experimental setup.
Fundamentally, the findings presented arose from the 
observation of increased apoptosis in liver biopsies of 
patients in the control arm without sevoflurane postcon-
ditioning from a randomized cohort of patients with I/R 
injury.12 Because an apoptotic effect of H/R on hepatocytes 
could not be confirmed in vitro, the interest shifted to HSCs 
and then to the effect of HSCs on hepatocytes. Therefore, 
supernatant transfer experiments were developed. If these 
findings can be confirmed, HSCs may be regarded as phar-
macological targets of halogenated volatile anesthetics in 
perioperative medicine.
In conclusion, our data suggest that sevoflurane-induced 
protection in H/R injury with apoptosis in hepatocytes is 
mediated through an attenuation of ROS production in 
HSCs. The role of HSCs and ROS in signaling of I/R injury 
to the liver has to be further explored. E
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Figure 5. Exposure of HEPs to supernatant of HSCs previously 
exposed to H/R: necrosis and apoptosis. HSCs were grown to con-
fluence and exposed to 6 h of hypoxia (0.2% oxygen) followed by 2 
h of reoxygenation in air to induce hypoxia-reperfusion (H/R) injury, 
with or without the presence of 2.2 Vol% sevoflurane or NAC as an 
antioxidant (10 μM). Supernatants were collected and transferred 
to a confluent layer of HEPs, followed by an incubation of 24 h. 
DNA quantitation in HEPs was performed (A, n = 4, ANOVA), and 
caspase activity was determined (B, n = 4, Kruskal-Wallis). Data 
are presented as mean ± SD. All values are displayed as propor-
tion of the control mean. *P < .001, #P < .001, $P < .001. ANOVA 
indicates analysis of variance; H/R, hypoxia/reoxygenation; HEP, 
hepatocyte; HSC, hepatic stellate cell; NAC, N-acetyl-cysteine; SD, 
standard deviation.
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